3.3 Cssmin plasma concentration
In the neoadjuvant treatment group, all patients initially received the
imatinib doses of 400 mg daily. The mean±SD (ranges) of the imatinib
Cssmin were 1858.7±1118.9 ng/mL (range 1083-4722 ng/mL).
In the adjuvant treatment group, 1 patient received 200 mg/d imatinib
and the imatinib Cssmin was 823 ng/mL. 4 patients
received 300 mg/d imatinib and the mean±SD (ranges) of the imatinib
Cssmin were 1216.6±705.9 ng/mL (range 584-2052 ng/mL). 9
patients received 400 mg/d imatinib and the mean±SD (ranges) of the
imatinib Cssmin were 1741.0±435.5 ng/mL (range
977.4-2252 ng/mL). 2 patients received 600 mg/d imatinib and the
imatinib Cssmin were 2692 ng/mL and 1446 ng/mL,
respectively. The distribution of imatinib in 25 GIST patients received
neoadjuvant imatinib therapy and adjuvant imatinib therapy was showed in
Figure 3.